Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Vanessa acquires Hungaro-Gal re Shylicine®

Vanessa Research (VRI) has acquired Hungaro-Gal, a Hungarian pharmaceutical contract manufacturing company. Per the acquisition, VRI will continue Hungaro-Gal’s contract manufacturing services and intends to maintain...

| By Kelley Gipson

Arvinas adds oncology, neurology experts to SAB

Arvinas has announced that six new thought leaders will join the company’s scientific advisory board. The new members are Tomasz M. Beer, M.D., F.A.C.P., Adam L....

| By Kelley Gipson

The microbiome and the nursing home

JAX and UConn researchers are exploring how patients’ microbiome, and risk of infection, change after time in a skilled nursing facility. A $778,801 grant from the National...

| By Kelley Gipson

Biohaven drug re ALS to be tested at Mass General

An experimental ALS drug being developed in New Haven will be tested next year in a first-of-its-kind clinical trial led by Massachusetts General Hospital. Biohaven Pharmaceuticals’...

| By Kelley Gipson

Bayer and Arvinas in protein degradation venture

Bayer and Arvinas have launched a new company, Oerth Bio, to leverage Arvinas’ expertise in targeted protein degradation and Bayer’s experience in developing human therapies and...

| By Kelley Gipson

FDA grants breakthrough status to Achillion drug

Achillion Pharmaceuticals reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients...

| By Kelley Gipson

2019 Entrepreneur of the Year nominations open

BioCT invites your nominations for the 2019 Entrepreneur of the Year Award. The Entrepreneur of the Year Award was established by BioCT and Shipman and...

| By Kelley Gipson

SpringWorks reports orphan drug designation

SpringWorks reports that the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft...

| By Kelley Gipson

Is 100 the new 50? JAX studies aging

Researchers at The Jackson Laboratory are using genomic technologies and specialized mouse models to decipher the changes that occur as a consequence of aging in...